Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
更正：一项随机II期临床试验，研究每周一次伊沙匹隆联合或不联合每两周一次贝伐珠单抗治疗铂类耐药或难治性卵巢癌/输卵管癌/原发性腹膜癌的疗效。
期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-024-02628-4
Roque, Dana M; Siegel, Eric R; Buza, Natalia; Bellone, Stefania; Silasi, Dan-Arin; Huang, Gloria S; Andikyan, Vaagn; Clark, Mitchell; Azodi, Masoud; Schwartz, Peter E; Rao, Gautam G; Reader, Jocelyn C; Hui, Pei; Tymon-Rosario, Joan R; Harold, Justin; Mauricio, Dennis; Zeybek, Burak; Menderes, Gulden; Altwerger, Gary; Ratner, Elena; Santin, Alessandro D
